No clinically relevant or statistically significant differences were reported between groups with respect to death ( 28 [ 13 % ] patients who received uric acid vs 31 [ 16 % ] who received placebo ) , symptomatic intracerebral haemorrhage ( nine [ 4 % ] vs six [ 3 % ] ) , and gouty arthritis ( one [ < 1 % ] vs four [ 2 % ] ) .